Market
Will Neuralink's N1 implant receive FDA approval for human trials by end of 2025?
Yes • 50%
No • 50%
FDA announcements and press releases
Story
Neuralink's N1 Implant with 1,024 Electrodes Promises Thought-Controlled Interaction at 9.5 BPS for Paralysis Patients
Dec 16, 2024, 09:02 AM
Neuralink's N1 implant is being hailed as a groundbreaking technology that could revolutionize the way individuals with paralysis interact with the world. The coin-sized device integrates 1,024 electrodes across 64 ultra-thin threads, achieving a bandwidth of 9.5 Bits Per Second (BPS), which is approximately 50% of normal human capability. This technology allows users to control computers, play games, and type using only their thoughts. Elon Musk has highlighted the potential of Neuralink to restore full body mobility by transferring signals from the motor cortex past spinal injuries, a feat already demonstrated in animals. The advancements in this field are generating significant interest among investors and researchers, as they explore the implications for technology and medicine, particularly in enhancing human capabilities and treating conditions like paralysis.
View original story
Similar markets
No • 50%
Yes • 50%
Paralysis treatment • 25%
Blindness treatment • 25%
Other breakthrough • 25%
ALS treatment • 25%
Significant AI integration • 25%
Enables multi-device control • 25%
Other • 25%
Achieves full sensory feedback • 25%
No • 50%
Yes • 50%
Improved communication for paralyzed patients • 25%
Enhanced mobility for ALS patients • 25%
New treatment for epilepsy • 25%
Other significant milestone • 25%